NASDAQ:BOLD Audentes Therapeutics (BOLD) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free BOLD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.21▼$12.6550-Day Range$59.97▼$59.9752-Week Range$22.00▼$60.00Volume95,797 shsAverage Volume1.50 million shsMarket Capitalization$538.61 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsInsider TradesSocial MediaStock AnalysisAnalyst ForecastsCompetitorsInsider TradesSocial Media Get Audentes Therapeutics alerts: Email Address Audentes Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.6% Upside$23.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$8.20 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($4.13) to ($4.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector709th out of 908 stocksBiological Products, Except Diagnostic Industry114th out of 147 stocks 3.5 Analyst's Opinion Consensus RatingAudentes Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAudentes Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BOLD. Previous Next 0.0 Dividend Strength Dividend YieldAudentes Therapeutics does not currently pay a dividend.Dividend GrowthAudentes Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BOLD. Previous Next 0.6 News and Social Media Coverage Search Interest5 people have searched for BOLD on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Audentes Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,200,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Audentes Therapeutics is held by insiders.Percentage Held by Institutions96.33% of the stock of Audentes Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Audentes Therapeutics are expected to decrease in the coming year, from ($4.13) to ($4.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Audentes Therapeutics is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Audentes Therapeutics is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Audentes Therapeutics Stock (NASDAQ:BOLD)Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Read More Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. BOLD Stock News HeadlinesApril 26, 2024 | seekingalpha.comBOLD Boundless Bio, Inc.April 11, 2024 | bbc.co.ukBold GirlsApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 11, 2024 | businesswire.comBoundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsApril 11, 2024 | morningstar.comBoundless Bio Inc BOLDApril 8, 2024 | businesswire.comBoundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024March 27, 2024 | businesswire.comBoundless Bio Announces Pricing of Initial Public OfferingNovember 25, 2023 | cnn.comMarriott Bonvoy Bold credit card review 2023April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.November 4, 2023 | yahoo.comKristen Louelle Is Bold and Beautiful in These 4 Pics in Atlantic CityOctober 27, 2023 | usatoday.comWhat Top 25 upsets are coming this weekend? Bold predictions for Week 5 in college footballApril 27, 2023 | forbes.comHow Bold Leadership Can Help Or Hurt YouApril 23, 2023 | finance.yahoo.comBold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023April 18, 2023 | entrepreneur.comThe Benefits of Bold Leadership and How Leaders Can Develop a Bold MindsetApril 2, 2023 | usatoday.comFive bold predictions for the men's NCAA Tournament's Final FourMarch 26, 2023 | usatoday.comMen's NCAA Tournament 2023: 10 bold predictions for March MadnessMarch 23, 2023 | finance.yahoo.com5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceMarch 17, 2023 | forbes.comTikTok Has A New ‘Bold Glamour’ AI-Powered Filter, Here Are The RisksMarch 12, 2023 | yahoo.comYou but better? Not so fast. Unpacking TikTok's controversial 'Bold Glamour' filterJanuary 18, 2023 | news.yahoo.comOn King's holiday, daughter calls for bold action over wordsJanuary 17, 2023 | dailymail.co.ukIt's blue Monday... Let's embrace it says JO ELVIN, with this season's refreshingly bold take on the colourJanuary 13, 2023 | forbes.comPersonal And Career Success One Bold Move A DayJanuary 5, 2023 | theguardian.comLeBron exits LA and an American F1 star: our bold sports predictions for 2023November 14, 2022 | usatoday.comBold predictions for college football's Week 11 have Alabama and LSU on upset alertOctober 8, 2022 | nypost.comLEGO makes bold claim on how bricks affect mental healthAugust 24, 2022 | investing.comBOLD_old Historical DataAugust 22, 2022 | yahoo.comFDA approves first fast-acting oral drug for clinical depressionSee More Headlines Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2019Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BOLD CUSIPN/A CIK1628738 Webwww.audentestx.com Phone415-818-1001FaxN/AEmployees207Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$25.00 Low Stock Price Target$20.00 Potential Upside/Downside+90.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-128,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-38.00% Debt Debt-to-Equity RatioN/A Current Ratio12.80 Quick Ratio12.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.48) per share Price / Book-1.61Miscellaneous Outstanding Shares46,272,000Free FloatN/AMarket Cap$558.50 million OptionableNo Data Beta2.18 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Matthew R. Patterson (Age 47)Co-Founder, Chairman & CEO Ms. Natalie C. Holles (Age 46)Pres & COO Mr. Thomas P. Soloway (Age 52)Exec. VP & CFO Dr. John T. Gray (Age 56)Sr. VP & Chief Scientific Officer Mr. Andrew H. ChangDirector of Investor RelationsKey CompetitorsAlectorNASDAQ:ALECC4 TherapeuticsNASDAQ:CCCCTaysha Gene TherapiesNASDAQ:TSHAFate TherapeuticsNASDAQ:FATEHumacyteNASDAQ:HUMAView All CompetitorsInsidersRa Capital Management, L.P.Bought 312,500 shares on 4/2/2024Total: $5 M ($16.00/share)Kristina BurowBought 200,000 shares on 4/2/2024Total: $3.20 M ($16.00/share)View All Insider Transactions BOLD Stock Analysis - Frequently Asked Questions Should I buy or sell Audentes Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BOLD shares. View BOLD analyst ratings or view top-rated stocks. What is Audentes Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 1-year target prices for Audentes Therapeutics' stock. Their BOLD share price targets range from $20.00 to $25.00. On average, they expect the company's share price to reach $23.00 in the next year. This suggests a possible upside of 97.6% from the stock's current price. View analysts price targets for BOLD or view top-rated stocks among Wall Street analysts. How were Audentes Therapeutics' earnings last quarter? Audentes Therapeutics Inc (NASDAQ:BOLD) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.07. During the same period in the prior year, the firm posted ($0.97) earnings per share. What other stocks do shareholders of Audentes Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer (ET), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Intel (INTC), Clovis Oncology (CLVS), AbbVie (ABBV), bluebird bio (BLUE), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN). When did Audentes Therapeutics IPO? Audentes Therapeutics (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at $16.00 per share. When does Audentes Therapeutics' quiet period expire? Audentes Therapeutics' quiet period expires on Tuesday, May 7th. Audentes Therapeutics had issued 6,250,000 shares in its public offering on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. During Audentes Therapeutics' quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. This page (NASDAQ:BOLD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
